On March 20, Rigerna Therapeutics (Suzhou Xuanjing Biotechnology Co., Ltd.) announced the completion of a Pre‑A financing round totaling over 200 million yuan, led by Kangjun Capital. Participating investors include Delian Capital, Huatai‑GenScript Fund, Jinyi Fuxin, Guohai Innovation Capital, Lenovo Capital, and existing shareholder Yuanxi Haihe Fund, Xuanjing Biological.

Founded in 2022, Rigerna Therapeutics is innovation‑driven and focuses on nephrology and metabolic diseases, aiming to become a leader and innovator in the small nucleic acid (oligonucleotide) pharmaceutical field Xuanjing Biological. With forward‑looking strategic planning, its lead pipeline has entered Phase II clinical trials and is poised to become the world’s first approved small nucleic acid drug for IgA nephropathy. Addressing unmet clinical needs in renal and metabolic disorders, Rigerna is developing multiple First‑in‑class programs, building a multi‑layered, gradient pipeline matrix. The completion of this financing round and advancement of several BD collaborations have secured substantial cash reserves, laying a solid foundation for future growth. The company is actively recruiting top talent to join its team.

Dr. Yuanyu Huang, Founder of Rigerna Therapeutics: “We sincerely thank all new and existing shareholders for their trust and unwavering support! The successful completion of this financing not only provides robust financial backing for the company’s innovative development but also injects strong momentum into its future high‑speed growth. We will stay true to our mission and strategic positioning, fully advancing Rigerna’s development in this new phase. Driven by innovation, we will continue to break through extrahepatic delivery bottlenecks, build proprietary technologies and pipelines, accelerate clinical translation and development, and achieve the commercialization of innovative small nucleic acid drugs at an early date to benefit patients worldwide.”

Kangjun Capital: “Nephropathy is a global challenge and a field with huge potential for blockbuster drugs. We are delighted to see Rigerna’s breakthrough progress in this area. Its lead pipeline for IgA nephropathy is globally leading in development, and its proprietary technologies demonstrate the potential to target different renal cell types. Looking ahead, we look forward to working hand‑in‑hand with Rigerna to develop more First‑in‑class small nucleic acid drugs for nephropathy, benefiting the 800 million patients with kidney diseases worldwide.”

Delian Capital: “With continuous breakthroughs in delivery technologies and drug R&D, siRNA drugs have entered a golden era of commercialization and rapid pipeline expansion, thanks to their high specificity, long‑lasting efficacy, and broad application potential. Rigerna’s core team has deep expertise in siRNA for many years, with a complete R&D system and outstanding execution and organizational efficiency. Leveraging foundational innovation, the company has built a highly differentiated pipeline with clear clinical value. Its lead program is advancing rapidly and is expected to be among the world’s first siRNA therapies for IgA nephropathy to enter pivotal clinical trials. Meanwhile, the company has achieved major breakthroughs in cutting‑edge areas such as renal‑targeted delivery and dual‑target siRNA, with multiple programs poised to enter clinical stages. Rigerna has attracted top industrial investors in previous financing rounds, with highly synergistic industrial resources. We expect Rigerna to lead the small nucleic acid drug industry into the 2.0 era, rooted in foundational innovation and centered on clinical value.”

Huatai‑GenScript Fund: “Rigerna Therapeutics is a highly promising innovator in the small nucleic acid sector. Its core team has over a decade of deep industry experience, with solid foundational technology accumulation, profound insights into clinical needs, and efficient execution. We are optimistic about Rigerna’s breakthroughs in extrahepatic targeted delivery technologies and the broad application prospects of its existing pipelines in complement‑mediated diseases. We look forward to Rigerna continuing to deepen its presence in the small nucleic acid drug field, bringing innovative therapies to global patients at an early date, and becoming a benchmark for Chinese innovative drugs going global.”

Jinyi Fuxin: “Since its establishment, Rigerna has achieved impressive R&D progress, fully demonstrating the team’s outstanding foresight and execution. Rigerna is one of the few global innovators that has established a ‘universal’ modification technology platform and broken through extrahepatic delivery technical barriers through multiple proprietary strategies. Its gradient‑differentiated pipeline layout in chronic diseases such as nephropathy and cardiovascular diseases reflects precise grasp of unmet clinical needs and validates a complete path from technology development to industrial transformation. We look forward to Rigerna opening a new era of nucleic acid drug therapy.”

Guohai Innovation Capital: “With its globally rare universal modification and extrahepatic delivery platforms, Rigerna has built a differentiated pipeline in nephropathy and metabolic diseases, demonstrating strong innovation capabilities and global competitiveness. We highly recognize the team’s professionalism and strategic vision. It is our great honor to participate in this financing round, and we will support the team in accelerating pipeline advancement and clinical translation, safeguarding life and health with innovative achievements.”

Lenovo Capital: “The small nucleic acid drug sector is currently in a period of rapid expansion following technological breakthroughs, with continuously expanding market space. With forward‑looking strategic planning and efficient R&D execution, Rigerna has built a multi‑layered, progressive pipeline matrix. Its lead pipeline ranks among the global first echelon, and the company continues to make breakthroughs in cutting‑edge technologies such as renal‑targeted delivery, demonstrating strong innovation capabilities and global competitiveness. Lenovo Capital highly values industrial transformation driven by cutting‑edge biotechnologies. We are delighted to partner with Rigerna and will actively serve as a reliable long‑term partner and bridge between capital and the life sciences, healthcare industry, biotech companies, and medical device firms.”

About Delian Capital

Founded in 2011, Delian Capital has long focused on technology and innovative healthcare, with key investments in sectors including pan‑semiconductors, energy technology, intelligent equipment, artificial intelligence, innovative drugs, and medical technology. The firm identifies early‑stage investment opportunities in technologically innovative enterprises and has invested in over 100 companies, including Xinzhou Technology, Anqiwei, Nanjing Hongtai, Yingchuang Huizhi, Luoshi Robotics, Mekamon, Fit2Cloud, Qiming Medical, Amunix, Core Medical, Orange Sail Pharma, and SeekGene.

About Huatai‑GenScript Fund

The Huatai‑GenScript Fund is a joint venture between Huatai Zijin and GenScript. Huatai Zijin is a wholly‑owned subsidiary of Huatai Securities (601688.SH) engaged in private equity investment, leveraging Huatai Securities’ full‑business‑chain advantages to provide comprehensive capital services to partners. The firm manages over 60 billion yuan across multiple funds, including PE, M&A, FOF, and industry‑focused funds. GenScript Biotech Corporation (HK.1548) is a global leader in life science R&D and manufacturing services. Rooted in robust DNA synthesis technology, GenScript has established four core business segments: life science services and products, biologic CDMO, industrial synthetic products, and cell therapy. GenScript collaborates with partners to accelerate scientific discovery and therapeutic breakthroughs, with operations covering over 100 countries and regions and serving more than 200,000 customers worldwide.

About Jinyi Fuxin

Wuxi Jinyi Fuxin Biomedical Venture Capital Partnership (LP), established in May 2024 and located in Wuxi’s Huishan District, is an industrial fund jointly funded by Wuxi Innovation Investment Group, Jiangsu Yuanli Industrial Investment, and Beijing Joinn Laboratories. With a fund size of 1 billion yuan, it primarily invests in life and health sectors, including biomedicine, life sciences, technologies addressing major unmet clinical needs, innovative breakthrough technologies, medical devices, and CROs. Leveraging Wuxi’s strong biomedical industry foundation, Jinyi Fuxin aims to integrate industrial chain resources through professional investment operations, build an internationally competitive biomedical industry cluster, and comprehensively promote the high‑quality development of Wuxi’s biomedical industry.

About Guohai Innovation Capital

Guohai Innovation Capital is a leading domestic securities‑affiliated private equity fund subsidiary and the private equity investment platform of Guohai Securities. It has been consecutively named one of China’s Top 10 Securities Private Equity Fund Managers and among the Top 100 Best Private Equity Investment Institutions from 2019 to 2025. The firm has launched and managed multiple primary and pre‑IPO equity funds, including listed company private placement and block trade funds, growth‑stage equity funds, sector‑thematic funds, and mezzanine M&A funds, as well as S‑strategy funds, with total AUM exceeding 21.4 billion yuan.
Guohai Innovation Capital boasts a professional investment team with backgrounds in industry, investment banking, law, and accounting. Focusing on the two core themes of “technological innovation” and “healthy living”, the firm has long invested in national strategic emerging and modern industries, including healthcare, new energy, new materials, next‑generation information technology, and aerospace. It has invested in over 100 leading enterprises in their respective sectors. Adhering to the investment philosophy of prudence, value investing, and win‑win cooperation, Guohai Innovation Capital provides comprehensive capital market operations and value‑added services to portfolio companies, supporting their growth while delivering stable, high‑quality long‑term returns to shareholders and investors.

About Lenovo Capital

Lenovo Capital and Incubator Group (LCIG), founded in 2016, is the global technology industry fund under Lenovo Group. It aims to integrate Lenovo’s global resources, invest in and incubate future‑focused technologies. LCIG has invested in over 300 outstanding enterprises. Through its innovative CVC 2.0 model, it fully leverages Lenovo’s industrial advantages in global branding, channels, and supply chains, building bridges for business collaboration between portfolio companies and Lenovo Group. This drives the industrialization of cutting‑edge technologies and fosters an ecosystem of complementary strengths and close collaboration for mutual success.

About Yuanxi Haihe Fund

The Yuanxi Haihe Fund is a collaboration between CanSino Biologics and GSR United Capital. It aims to build and maintain an innovative and synergistic biomedical ecosystem, rooted in and serving the industry, and promoting the coordinated development of capital and industry through a win‑win approach. By integrating CanSino Biologics’ and GSR United Capital’s rich industrial resources and professional investment management expertise, this partnership is expected to create more opportunities and drive innovation in the biomedical industry, advance medical technology, and contribute to global human health.